RT Journal Article
SR Electronic
T1 A systematic review of the smartphone applications available for corona virus disease 2019 (COVID19) and their assessment using the mobile app rating scale (MARS)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.02.20144964
DO 10.1101/2020.07.02.20144964
A1 Davalbhakta, Samira
A1 Advani, Shailesh
A1 Kumar, Shobhit
A1 Agarwal, Vishwesh
A1 Bhoyar, Samruddhi
A1 Fedirko, Elizabeth
A1 Misra, Durga Prasanna
A1 Goel, Ashish
A1 Gupta, Latika
A1 Agarwal, Vikas
YR 2020
UL http://medrxiv.org/content/early/2020/07/04/2020.07.02.20144964.abstract
AB The global impact of COVID-19 pandemic has increased the need to rapidly develop and improve utilization of mobile applications across the healthcare continuum to address rising barriers of access to care due to social distancing challenges and allow continuity in sharing of health information, assist with COVID-19 activities including contact tracing, and providing useful information as needed. Here we provide an overview of mobile applications being currently utilized for COVID-19 related activities. We performed a systematic review of the literature and mobile platforms to assess mobile applications been currently utilized for COVID-19, and quality assessment of these applications using the Mobile Application Rating Scale (MARS) for overall quality, Engagement, Functionality, Aesthetics, and Information. Finally, we provide an overview of the key salient features that should be included in mobile applications being developed for future use. Our search identified 63 apps that are currently being used for COVID-19. Of these, 25 were selected from the Google play store and Apple App store in India, and 19 each from the UK and US. 18 apps were developed for sharing up to date information on COVID-19, and 8 were used for contact tracing while 9 apps showed features of both. On MARS Scale, overall scores ranged from 2.4 to 4.8 with apps scoring high in areas of functionality and lower in Engagement. Future steps should involve developing and testing of mobile applications using assessment tools like the MARS scale and the study of their impact on health behaviors and outcomes.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020180878 Funding StatementNo funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocol registered on PROSPERO- https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020180878All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available as tables and figures submitted along with the manuscript.